RADA16 use in Plastic surgery (facelift): a pilot study with an optimised application technique

The facelift is one of the most common cosmetic surgeries performed. Although the procedure is...

3-D Matrix keeps aiming in the ENT and Plastic Surgery medical areas with PuraBond

The 3-D Matrix agenda keeps being filled with a selection of events, including those dedicated to...

PuraStat becomes PuraBond for cardiac surgeons in Spain

In conjunction with its participation at the XXVI edition of the Secce’s congress in Oviedo, 3-D...

The Global PuraStat Dinner Grandior Hotel Prague on Thursday 28th April 2022

On Thursday 28th April 2022, 3-D Matrix, in collaboration with FUJIFILM, hosted their first global ...

First clinical data demonstrating PuraStat’s safety and efficacy for haemostasis in thyroidectomy and parathyroidectomy. A case series of 353 patients.

Cervical endocrine surgeries such as thyroidectomy and parathyroidectomy can carry the risk of...

US Notice Regarding Marketing Approval for Radiation Proctitis Wound Healing Material

We are pleased to announce that the 510K submitted to the United States Food and Drug...

3-D Matrix ranked in the Top 500 Fastest Growing Companies in Asia-Pacific region published by Financial Times

We are pleased to share that 3-D Matrix has been ranked 179th on the list of the 500...

Meet the Expert in Germany -  PuraStat: Looking Beyond Haemostasis

On the 23rd of February, 3-D Matrix continued its Meet the Expert series with "PuraStat: Looking...

PuraStat as an effective adjunct therapy for intraprocedural Endoscopic retrograde cholangiopancreatography (ERCP) bleeding: a new case report from Italy.

Endoscopic sphincterotomy is frequently performed during ERCP and bleeding can represent a severe...

Notice regarding the submission for new manufacturing process for haemostatic products in Europe

We are pleased to announce that on the 13th January 2022, our European subsidiary 3-D Matrix Europe...